Zydus Lifesciences appoints Shelina Parikh as Additional Director, Independent Director

Ahmedabad: Zydus Lifesciences has approved the appointment of Shelina Parikh as an Additional Director as well as Independent Director of the Company for the first term
of 5 (five) consecutive years.

Shelina Parikh is the Joint Managing Director of TechNova Group, a privately held, family business group with interests in imaging solutions, chemicals and
industrial products.
Its main company, TechNova Imaging Systems, is the largest manufacturer of
offset and digital print solutions in India, and the fifth largest in the world.
TechNova’s business portfolio covers Specialty Chemicals, Offset Printing
Plates, Digital Print Media and Digital Print Equipment & Software. Globally
recognised as a pioneer, TechNova’s innovative products cater to a range of
industries such as Commercial & Newspaper Printing, Packaging, Publishing,
Signage, Photo, Textile and Medical Imaging.
As Joint MD, she is passionate about innovation, technology and mentoring
leaders. She is instrumental in strengthening TechNova’s strategic
operations, business transformation, market leadership position, digitisation
and new growth engines.
Her emphasis on the spiritual values of zero-ego, humility, trust,
transparency, kindness and life-time employment are combined with a focus
on high performance metrics, passion for excellence, leaner structures and
strong corporate governance. This unique ethos has established a vibrant,
innovative organisation that is recognised as a global leader in the Imaging
Industry.
She is a member of Young Presidents Organisation and a founding member
of Entrepreneurs Organisation in India.
She completed her B.A. from Brown University and MBA from Harvard
Business School. She remains engaged with Harvard Business School, as Vice
President of the HBS Global Alumni Board and member of the HBS South Asia
Advisory Board.

Headquartered in Ahmedabad, Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer-related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. 

Read also: Zydus Lifesciences completes enrolment for EPICS III Phase 2b/3 trial evaluating Saroglitazar Mg for Primary Biliary Cholangitis

Facebook Comments